VIA
CRNX icon

Virtus Investment Advisers’s Crinetics Pharmaceuticals CRNX Stock Holding History

Virtus Investment Advisers’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$607K Buy
16,721
+3,186
+24% +$142K 0.17% 194
2025
Q4 		$630K Buy
13,535
+9,998
+283% +$445K 0.17% 216
2025
Q3 		$147K Buy
3,537
+614
+21% +$19.6K 0.04% 378
2025
Q2 		$84.1K Sell
2,923
-30
-1% -$926 0.03% 406
2025
Q1 		$99K Buy
+2,953
New +$110K 0.03% 422

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Virtus Investment Advisers's CRNX Position: Q1 2026 in Review

Virtus Investment Advisers increased its Crinetics Pharmaceuticals (CRNX) stake by 24% in Q1 2026, buying an estimated $142K and bringing the position to 16,721 shares worth $607K. The position accounts for 0.17% of the portfolio, ranked #194.

Virtus Investment Advisers first reported a position in CRNX in Q1 2025 and has held it in 5 quarters since. The position peaked at $630K in Q4 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Virtus Investment Advisers held 16,721 shares of Crinetics Pharmaceuticals worth $607K as of Q1 2026.
  • Virtus Investment Advisers bought 3,186 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $142K.
  • Crinetics Pharmaceuticals made up 0.17% of Virtus Investment Advisers's portfolio in Q1 2026, its #194 holding.
  • Virtus Investment Advisers first reported a position in Crinetics Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Virtus Investment Advisers's Crinetics Pharmaceuticals position peaked at $630K in Q4 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Virtus Investment Advisers's 13F filing for Q1 2026, filed 14 May 2026.